IN8BIO INC (INAB)

Company Profile

IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company is headquartered in New York City, New York and currently employs 31 full-time employees. The company went IPO on 2020-11-12. The firm is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. The firm's lead program, INB-400, is in a Phase II clinical trial in which autologous, genetically modified gamma-delta T cells are assessed in glioblastoma (GBM). Its additional programs include Phase I trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for the treatment of patients with hematologic malignancies that are undergoing hematopoietic stem cell transplantation (HSCT). In addition, the Company’s DeltEx platform has yielded a portfolio of preclinical programs, including INB-300 and INB-500, focused on addressing acute myeloid leukemia (AML) and other solid and hematological tumor types.

Company Info

IN8BIO INC

Empire State Building, 350 5Th Avenue, Suite 5330

New York City NEW YORK

P: 16466006438

CEO: William Ho

Employees: 39

Website: https://www.in8bio.com